Home > Insider Trading > Filing (0001415889-24-027861)

Filing Details

Accession Number:: 0001415889-24-027861
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-11-27 16:39:29
Reporting Period:: 2024-11-26

Accepted Time:: 2024-11-27 16:39:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1404644	Neurogene Inc.	NGNE	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1253170	Srinivas Akkaraju	C/O Samsara Biocapital 628 Middlefield Road Palo Alto CA 94301	No	No	Yes	No
1699737	Samsara Biocapital, L.p.	628 Middlefield Road Palo Alto CA 94301	No	No	Yes	No
1888829	Samsara Biocapital Gp, Llc	628 Middlefield Road Palo Alto CA 94301	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-11-26	20,748	$24.91	1,689,105	No	4	P	Indirect	By Samsara BioCapital, L.P.
Common Stock	Acquisiton	2024-11-26	10,803	$26.01	1,699,908	No	4	P	Indirect	By Samsara BioCapital, L.P.
Common Stock	Acquisiton	2024-11-26	15,219	$26.73	1,715,127	No	4	P	Indirect	By Samsara BioCapital, L.P.
Common Stock	Acquisiton	2024-11-26	2,000	$27.50	1,717,127	No	4	P	Indirect	By Samsara BioCapital, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Samsara BioCapital, L.P.
No	4	P	Indirect	By Samsara BioCapital, L.P.
No	4	P	Indirect	By Samsara BioCapital, L.P.
No	4	P	Indirect	By Samsara BioCapital, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.